U.S. Markets closed
  • S&P 500

    3,785.38
    -33.45 (-0.88%)
     
  • Dow 30

    30,775.43
    -253.88 (-0.82%)
     
  • Nasdaq

    11,028.74
    -149.16 (-1.33%)
     
  • Russell 2000

    1,707.99
    -11.38 (-0.66%)
     
  • Crude Oil

    105.78
    -4.00 (-3.64%)
     
  • Gold

    1,806.80
    -10.70 (-0.59%)
     
  • Silver

    20.23
    -0.51 (-2.45%)
     
  • EUR/USD

    1.0487
    +0.0043 (+0.4090%)
     
  • 10-Yr Bond

    2.9720
    -0.1210 (-3.91%)
     
  • Vix

    28.65
    +0.49 (+1.74%)
     
  • GBP/USD

    1.2173
    +0.0050 (+0.4163%)
     
  • USD/JPY

    135.7090
    -0.8360 (-0.6123%)
     
  • BTC-USD

    18,998.72
    -1,315.54 (-6.48%)
     
  • CMC Crypto 200

    407.64
    -23.83 (-5.52%)
     
  • FTSE 100

    7,169.28
    -143.04 (-1.96%)
     
  • Nikkei 225

    26,393.04
    -411.56 (-1.54%)
     

Verastem (NASDAQ:VSTM) investors are sitting on a loss of 62% if they invested three years ago

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

If you love investing in stocks you're bound to buy some losers. But the long term shareholders of Verastem, Inc. (NASDAQ:VSTM) have had an unfortunate run in the last three years. So they might be feeling emotional about the 62% share price collapse, in that time. And more recent buyers are having a tough time too, with a drop of 51% in the last year. The falls have accelerated recently, with the share price down 56% in the last three months.

With that in mind, it's worth seeing if the company's underlying fundamentals have been the driver of long term performance, or if there are some discrepancies.

See our latest analysis for Verastem

Verastem recorded just US$1,112,000 in revenue over the last twelve months, which isn't really enough for us to consider it to have a proven product. This state of affairs suggests that venture capitalists won't provide funds on attractive terms. So it seems shareholders are too busy dreaming about the progress to come than dwelling on the current (lack of) revenue. For example, they may be hoping that Verastem comes up with a great new product, before it runs out of money.

We think companies that have neither significant revenues nor profits are pretty high risk. You should be aware that there is always a chance that this sort of company will need to issue more shares to raise money to continue pursuing its business plan. While some such companies go on to make revenue, profits, and generate value, others get hyped up by hopeful naifs before eventually going bankrupt. Verastem has already given some investors a taste of the bitter losses that high risk investing can cause.

When it last reported its balance sheet in September 2021, Verastem had cash in excess of all liabilities of US$87m. While that's nothing to panic about, there is some possibility the company will raise more capital, especially if profits are not imminent. We'd venture that shareholders are concerned about the need for more capital, because the share price has dropped 17% per year, over 3 years. You can click on the image below to see (in greater detail) how Verastem's cash levels have changed over time.

debt-equity-history-analysis
debt-equity-history-analysis

It can be extremely risky to invest in a company that doesn't even have revenue. There's no way to know its value easily. What if insiders are ditching the stock hand over fist? It would bother me, that's for sure. It only takes a moment for you to check whether we have identified any insider sales recently.

A Different Perspective

While the broader market gained around 2.8% in the last year, Verastem shareholders lost 51%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. On the bright side, long term shareholders have made money, with a gain of 1.2% per year over half a decade. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. It's always interesting to track share price performance over the longer term. But to understand Verastem better, we need to consider many other factors. Case in point: We've spotted 4 warning signs for Verastem you should be aware of.

If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.